Faron press release February 23:
TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunotherapies, today announces that data from its Phase I/II BEXMAB trial evaluating bexmarilimab in combination with azacitidine for the treatment of higher-risk myelodysplastic syndromes (MDS) have been accepted for presentation at the 66th Annual Scientific Meeting of the British Society for Haematology (BSH), taking place 19–21 April 2026 in Liverpool, UK.
Do I understand correctly that the poster specifies: (presenting author)
Dr Emma Searle The Christie NHS Foundation Trust and the University of Manchester
AND that no Faron personnel are at least featured?
It would be worth starting to look for the abstract matching the title since the conference starts today.